Thin
1 / 2
Linaclotide is a prescription medicine that has been clinically proven to be effective in treating irritable bowel syndrome (IBS-C) and chronic enteroendocrine syndrome (CIC). Its mechanism of action is to increase intestinal fluid secretion, thereby softening stool and promoting regular bowel movements. This mechanism of action not only promotes bowel movements, but also relieves the discomfort caused by constipation, such as bloating, abdominal pain and straining during bowel movements.
Linaclotide is a guanylate cyclase-C agonist that enhances intestinal fluid secretion and accelerates transit, commonly used in research on chronic constipation and irritable bowel syndrome with constipation (IBS-C).
Linaclotide, approved clinically for chronic idiopathic constipation and IBS‑C, typically comes in microgram doses (e.g., 72 mcg, 145 mcg, 290 mcg capsules in clinical settings). Research applications should reflect standard mg‑to‑mcg scaling and follow rigorous protocols.
Linaclotide is clinically proven for managing irritable bowel syndrome with constipation (IBS-C) and chronic enteroendocrine syndrome/chronic idiopathic constipation (CIC).
As a guanylate cyclase-C agonist, it triggers intestinal fluid secretion to soften stools, accelerates gastrointestinal transit, and encourages regular bowel motility.
Yes. In addition to promoting bowel movements, Linaclotide relieves abdominal discomfort, bloating, and painful straining during defecation.
In clinical settings, Linaclotide is administered in microgram doses, standardly packaged in strengths such as 72 mcg, 145 mcg, and 290 mcg capsules.
Research investigations should apply standard mg-to-mcg conversion scaling and adhere strictly to controlled laboratory experimental protocols.
No. Research-grade Linaclotide compounds are explicitly manufactured for research purposes and are not intended for direct clinical application.
